Application of boron carbide particles to boron neutron capture therapy
Project/Area Number |
25670857
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Surgical dentistry
|
Research Institution | Osaka University |
Principal Investigator |
YURA YOSHIAKI 大阪大学, 歯学研究科(研究院), 教授 (00136277)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 口腔扁平上皮癌 / 中性子 / ホウ素化合物 / 炭化ホウ素球 / 超音波照射 / 溶媒 / 可溶化溶媒 / 水溶性ポリマー / 炭化ホウ素 / ホウ素中性子捕捉療法 / 炭化ホウ素粒 |
Outline of Final Research Achievements |
Boronophenylalanine (BPA)is a major boron compound used in boron neutron capture therapy (BNCT)for cancer patients. Boron-rich boron carbide (B4C) nanoparticles are novel compounds containing a large number of born molecules. The tumor volume was smaller in B4C-mediated BNCT group than in neutron group. Purebright MB was found to solubilize B4C particles. This suggests that B4C particles injected intratumorally act as boron compounds for BNCT.
|
Report
(4 results)
Research Products
(18 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Boron neutron capture therapy for recurrent head and neck malignancies without other treatment options.
Author(s)
Kato I, Yamamoto N, Fujita Y, Ohmae M, Sakurai Y, Kumada H, Murata I, Miyamaru H, Maruhashi A, Kirihata M, Imahori Y, Suzuki M, Sumi T, Iwai S, Nakazawa M, Yura Y, Ono K
Organizer
6th Trilateral Meeting on BNCT Meeting between Taiwan and Japan
Place of Presentation
Taipei Veterans General Hospital (Taiwan)
Related Report
Invited
-